Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 11/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8999489 | 0.92 | ABL1 (0.44) | ABL1PIK3CA | |
| SCHEMBL8999669 | 0.92 | ABL1 (0.43) | ABL1 | |
| SCHEMBL8998631 | 0.91 | ABL1 (0.41) | ABL1 | |
| SCHEMBL13752555 | 0.91 | PIK3CD (0.40) | ABL1PIK3CDPIK3CA | |
| SCHEMBL8999978 | 0.89 | ABL1 (0.42) | ABL1 | |
| SCHEMBL8998585 | 0.89 | POLB (0.42) | ABL1 | |
| SCHEMBL10046924 | 0.89 | ABL1 (0.40) | ABL1 | |
| SCHEMBL8999608 | 0.89 | ABL1 (0.41) | ABL1 | |
| SCHEMBL8999581 | 0.89 | ABL1 (0.41) | ABL1 | |
| SCHEMBL8999540 | 0.87 | ABL1 (0.41) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023525-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-24 | — | — | US | disclosed |
| US-20130023525-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-24 | — | — | US | disclosed |
| US-8193352-B2 | 2-(3-Ethyl-ureido)-6-pyridin-3-yl-3H-benzoimidazole-4-carboxylic acid methyl ester; for treating bacterial infections in mammals; useful in treating or lessening severity of urinary tract infections, pneumonia, prostatitis, skin and soft tissue infections, intra-abdominal infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193352-B2 | 2-(3-Ethyl-ureido)-6-pyridin-3-yl-3H-benzoimidazole-4-carboxylic acid methyl ester; for treating bacterial infections in mammals; useful in treating or lessening severity of urinary tract infections, pneumonia, prostatitis, skin and soft tissue infections, intra-abdominal infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-05 | — | — | US | disclosed |
| US-8188095-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188095-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120010222-A1 | Gyrase Inhibitors and Uses Thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010222-A1 | Gyrase Inhibitors and Uses Thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-12 | — | — | US | disclosed |
| US-8067606-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067606-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-29 | — | — | US | disclosed |
| US-7582641-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582641-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-01 | — | — | US | disclosed |
| US-7569591-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569591-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-08-04 | — | — | US | disclosed |
| US-20090176771-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-20090176771-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| EP-1592686-B1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2009-07-08 | — | — | EP | disclosed |
| EP-1789419-B1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2009-06-17 | — | — | EP | disclosed |
| US-7495014-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495014-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010222-A1 | Gyrase Inhibitors and Uses Thereof | TOP1, TOP2A, NQO2 | ABL1 1016/4885PIK3CD 3207/4885PIK3CA 2541/4885 |
| US-20090176771-A1 | GYRASE INHIBITORS AND USES THEREOF | TOP1, TOP2A, TOP2B | ABL1 460/4885PIK3CD 636/4885PIK3CA 472/4885 |
| US-20130023525-A1 | GYRASE INHIBITORS AND USES THEREOF | TOP1, TOP2A, TOP2B | ABL1 460/4885PIK3CD 636/4885PIK3CA 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.